Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non–small‐cell lung cancer
Abstract Lung cancer remains the leading cause of cancer death throughout the world. Despite new chemotherapeutic, immunomodulating and molecularly targeted agents, patients with locally advanced or metastatic disease still have a poor prognosis. This trial looked to combine antiangiogenic therapy w...
Сохранить в:
| Главные авторы: | , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Wiley
2018-07-01
|
| Серии: | Cancer Medicine |
| Предметы: | |
| Online-ссылка: | https://doi.org/10.1002/cam4.1569 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|